Doxorubicin hydrochloride liposome injection is an anthracycline topoisomerase II inhibitor indicated for: • Ovarian cancer (1.1) After failure of platinum-based chemotherapy. • AIDS-related Kaposi’s Sarcoma After failure of prior systemic chemotherapy or intolerance to such therapy. • Multiple Myeloma In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy.
